The Innovative Licensing and Access Pathway grants Innovation Passports to investigational products for cancer and dementia
The UK’s Innovative Licensing and Access Pathway (ILAP) has awarded Innovation Passports to two investigational medicines for liver cancer and dementia, enabling earlier regulatory and market access support.
The UK’s Innovative Licensing and Access Pathway (ILAP) has granted Innovation Passports to two investigational medicines targeting liver cancer and dementia. The designation is awarded to products that may address unmet clinical needs and offer significant patient benefits. The ILAP is a collaboration between the MHRA, NHS England, NICE, the Scottish Medicines Consortium, the All Wales Therapeutics and Toxicology Centre, and the Department of Health Northern Ireland.
Liver cancer, specifically hepatocellular carcinoma, affects around 7,000 people annually in the UK, while dementia with Lewy bodies impacts approximately three in twenty dementia patients. Treatment options for both conditions remain limited. The Innovation Passport provides developers with coordinated regulatory and market access guidance to accelerate development and potential patient access.
The ILAP facilitates early and ongoing engagement between developers, the MHRA, HTA bodies, and the NHS to streamline processes and support the development of innovative medicines. The awarded products are still in development, and future availability depends on evidence of safety, effectiveness, and value. Companies developing medicines for unmet patient needs across all therapeutic areas are encouraged to apply.
Applications for the next ILAP round open on 4 August 2026 and close on 4 November 2026. The pathway is open to commercial and non-commercial developers worldwide, provided their medicines have not yet entered confirmatory trials. Further details are available on the MHRA website.